OncoFusion Therapeutics Reacquires Rights to BET Bromodomain Inhibitors

ANN ARBOR, MI — (January 15, 2016) – OncoFusion Therapeutics, Inc. announced today that it has reached an agreement with Medivation, Inc. to reacquire the rights to certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins identified and developed under a research and license agreement announced between the parties in April 2014.


OncoFusion plans to advance development into clinical trials. As a selective inhibitor of BET bromodomain proteins, if it is ultimately approved for marketing, such a compound could provide a treatment for a wide range of cancers including castrate-resistant prostate cancer.


About BET Bromodomain Proteins

BET bromodomain proteins regulate gene expression and have been shown to play a critical role in cancer and other diseases. Emerging research in the area of cancer biology suggests that targeting epigenetic regulators such as the bromodomain family of proteins may reduce the growth of a number of tumor types including certain hematological and solid tumors. Recent preclinical data published in Nature1 reported that targeting BET bromodomain proteins may have therapeutic potential in castration-resistant prostate cancer that is resistant to current treatments.


1 Chinnaiyan, et al. Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer, Nature, DOI: 10.1038/nature13229, published online April 23, 2014.


About OncoFusion, Inc.

OncoFusion Therapeutics is a privately-held company, which was founded in 2012 by Arul M. Chinnaiyan, M.D., Ph.D.; Shaomeng Wang, Ph.D., and Kenneth J. Pienta, M.D. to develop technology discovered at the University of Michigan. OncoFusion’s mission is to discover and develop the next generation of personalized therapeutics for patients with genetically defined cancers. For more information, visit www.oncofusion.com.


Media Contact

Mike Beyer

Sam Brown Inc.